Gland Pharma posts 58% profit growth in Q2

Gland Pharma Limited GLAND reported Q2 FY27 consolidated revenue of ₹1,834 crore, an increase of 23% year-on-year. Net profit increased 58% to ₹290.8 crore. The company's CDMO business contributed 45% of revenue and grew 31% during the quarter. Critical Injectables accounted for the remaining 55%, with growth of 18%. Why this matters: Growth across both business segments indicates that the improvement was not restricted to one operating area. The company also reported an improvement in profitability, with adjusted EBITDA margin at approximately 27%. What to watch next: Investors should track growth in the CDMO business, new product launches, US regulatory approvals and research and development expenditure. My view: The quarter shows encouraging growth in revenue and profit. The next test is whether the company can maintain this growth while managing regulatory and pricing risks in international markets. Learning outcome: Pharmaceutical investors should examine product approvals, geographical exposure, segment growth and regulatory compliance alongside quarterly profit figures to understand the quality of earnings.